<DOC>
	<DOC>NCT01064570</DOC>
	<brief_summary>Prospective use of RT-PCR for PML/RARa might be used to guide a total tehrapy approach in APL, including refined diagnosis, front-line treatment, assessment of response and anticipated salvage therapy for patients who undergo molecular relapse.</brief_summary>
	<brief_title>AIDA 2000 Guidelines</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Promyelocytic, Acute</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<criteria>Age &gt;= 1 years and &lt; 61 years Morphologic diagnosis of APL PS &lt;= 3 Presence in leukemic cells at diagnosis of t(15;17), and/or PML/RARa rearrangement by RTPCR. T The presence of additional cytogenetic lesions is not considered an exclusion criterion Serum creatinine &lt;=2.5 mg/dL Serum bilirubin, alkaline phosphatase, or GOT/ASAT &lt;= 3 times the upper normal limit Negative pregnancy test Written informed consent Age &gt;= 61 years Prior antileukemic chemotherapy for APL Absence of PMLRARa rearrangement after successful RNA extraction and amplification of control gene Prior antileikemic chemotherapy for APL Presence of a concomitant malignant neoplasm, except basal cell carcinoma Concurrent treatment with cytotoxic chemotherapy or radiotherapy Oteher progressive malignant disease. However, secondary acute promyelocytic leukemia following "cured" Hodgkin's disease or otehr cured malignancies may be included, as well as secondary leukemias following other exposure to alkylating agents or radiation for other reasons</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Acute Promyelocytic Leukemia</keyword>
	<keyword>APL</keyword>
</DOC>